May 8, 2025 02:18 PM EDTUpdated May 9, 09:41 AM
Pharma
Law

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

Alexis Kramer

Deputy Editor

As­traZeneca lost its chal­lenge to Medicare drug price ne­go­ti­a­tions in the first ap­peals court rul­ing on the mer­its of the Biden-era pro­gram.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments 

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times